Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes
The specific aims of the study include:
- Profile the demographic, health-related, psychosocial and behavioral characteristics of adults with MEN1 or MEN2.
- Evaluate MEN-specific distress as well as adherence to surveillance regimens among adults with MEN1 or MEN2, and identify associated with those outcomes.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes|
- Profile the demographic, health-related, psychosocial and behavioral characteristics of adults with MEN1 or MEN2. [ Time Frame: 3 Years ] [ Designated as safety issue: No ]
|Study Start Date:||May 2007|
|Estimated Primary Completion Date:||May 2015 (Final data collection date for primary outcome measure)|
Patients with multiple endocrine neoplasia (MEN).
Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
Other Name: Survey
The proposed cross-sectional study is intended to obtain information regarding current surveillance behaviors and other psychosocial outcomes among persons affected by the multiple endocrine neoplasia (MEN) 1 or MEN2, which are inherited conditions.
Study participants will include patients who have been seen previously at MDACC for evaluation of MEN1 or MEN2. Because this is the first time investigators are contacting these patients to invite them to participate in psychosocial research, the proposed study also will help determine the feasibility of conducting similar studies in the future.
Investigators anticipate that data gathered from this study will enhance existing knowledge about the psychological and behavioral aspects of the MEN syndromes, and will inform future research efforts directed toward this understudied population.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00501449
|United States, Texas|
|UT MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Susan Peterson, PhD||M.D. Anderson Cancer Center|